logo-loader

OxSonics Therapeutics

Receive alerts
Market:
PRIVATE
Market Cap:
£0.00
Price
0.00 0
Change
0%
52 weeks high
0
52 weeks low
0

In brief

OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.